Related Experiment Videos
Clinical treatment regimens for chronic heart failure: a review
1Alfred Heart Centre, Commercial Rd, Prahran, Victoria 3181, Australia. d.kaye@alfred.org.au
Insights
Chronic heart failure (CHF) management is evolving, with pharmacotherapy and emerging biomedical engineering like biventricular pacing showing promise. This overview emphasizes current therapeutic strategies for heart failure patients.
Area of Science:
- Cardiology
- Pharmacology
- Biomedical Engineering
Background:
- Chronic heart failure (CHF) prevalence is rising globally, especially in the elderly, increasing healthcare costs.
- Systolic heart failure, often caused by ischemic heart disease, is the most common presentation.
- Diastolic heart failure accounts for 20-40% of CHF cases, frequently co-occurring with systolic dysfunction.
Purpose of the Study:
- To provide a comprehensive overview of current therapeutic strategies for chronic heart failure (CHF).
- To highlight the significant role of pharmacotherapy in managing CHF.
- To discuss emerging biomedical engineering approaches in heart failure treatment.
Main Methods:
- Review of extensive clinical trials on CHF pharmacotherapy.
- Analysis of evidence for angiotensin-converting enzyme inhibitors, beta-blockers, and spironolactone.
- Examination of early data from biventricular pacing and mechanical heart research.
Main Results:
- Robust evidence supports pharmacotherapy, including ACE inhibitors, beta-blockers, and spironolactone, for mortality and morbidity benefits in CHF.
- Biventricular pacing (cardiac resynchronization therapy) shows encouraging early results.
- Ischemic heart disease is the primary etiological factor in approximately 50% of CHF cases.
Conclusions:
- Pharmacotherapy remains a cornerstone in evidence-based CHF management.
- Biomedical engineering innovations like cardiac resynchronization therapy offer new therapeutic avenues.
- A multifaceted approach, integrating pharmacotherapy and advanced technologies, is crucial for effective CHF treatment.
Abstract:
Chronic heart failure (CHF) is increasing in prevalence worldwide, particularly in the elderly. Accordingly, this epidemic is likely to translate into a major increase in healthcare costs. Systolic heart failure is the most common cause of CHF presentations. Although the causes vary, the most common single aetiological factor is ischaemic heart disease, which accounts for approximately 50% of heart failure presentations. Research into CHF pharmacotherapy has been copious, with the focus principally centred on systolic heart failure. The evidence base for pharmacotherapy in CHF is amongst the largest currently in clinical medicine. There have been multiple trials establishing the mortality and morbidity benefits of pharmacotherapy. Amongst these, large scale trials of angiotensin-converting enzyme inhibitors, beta-blockers and spironolactone have provided a sound basis for evidence-based treatment approaches to the CHF patient. Recently research interest has increased in biomedical engineering with studies being performed in biventricular pacing and mechanical hearts. Early data with biventricular pacing or cardiac resynchronisation therapy is encouraging. Diastolic heart failure alone accounts for at least 20 - 40% of CHF presentations and whilst it may occur in isolation, is most commonly seen in association with systolic heart failure. In this study, we present a broad overview of the current therapeutic modalities for the management of CHF, with particular emphasis on pharmacotherapy.